Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AAPL
6. HOOD
7. QCOM
8. ACN
9. AZN
10. ROIV

Go back to Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences (NASDAQ: GILD) Delayed: 146.64 -4.36 (2.89%)
Previous Close $151.00    52 Week High $108.63 
Open $146.98    52 Week Low $71.39 
Day High $148.65    P/E 81.02 
Day Low $145.45    EPS $1.81 
Volume 6,080,492